Cysticercosis: Clinical Trials

26 trials for Cysticercosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

17 completed, 3 not yet recruiting, 3 terminated, 1 recruiting. 7 Phase 3, 6 Not applicable, 4 Phase 1, 3 Phase 2, 1 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 37Completed 4, Terminated 2, Not yet recruiting 1
Not applicable6Completed 5, Not yet recruiting 1
Phase 14Completed 3, Withdrawn 1
Phase 23Completed 1, Not yet recruiting 1, Terminated 1
Phase 41Not yet recruiting 1

Follow Cysticercosis: new trials by email Literature Review of Cysticercosis trials Research Report on Cysticercosis

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Oxfendazole in Mild Parenchymal Brain Cysticercosis
Oxfendazole single dose, Oxfendazole three doses, albendazole plus praziquantel regime - Brain Cysticercosis
Phase 2 / Phase 3Not yet recruitingUniversidad Peruana Cayetano Heredia5442026-12-012026-05-01
The Impact of Medical TV Drama in Improving Literacy on Neurocysticercosis
Medical TV Drama Episode (House M.D.) - Neurocysticercosis, Health Literacy
Not applicableNot yet recruitingCephas Health Research Initiative Inc, Ibadan, Nigeria602025-12-152025-12-04
Assessment of Combined Praziquantel and Albendazole vs Albendazole Alone to Treat Active Parenchymal Neurocysticercosis
albendazole and praziquantel, Albendazole - Neurocysticercosis
Phase 4Not yet recruitingR-Evolution Worldwide S.r.l. Impresa Sociale3002024-06-012024-04-23
Parenchymal and Extraparenchymal Neurocysticercosis-A Registry Based Study
Neurocysticercosis, Tropical Disease
UnknownAll India Institute of Medical Sciences10002021-01-152021-01-13
Investigation of Environmental Factors Associated With Transmission of T. Solium in Endemic Villages of Zambia
Neurocysticercosis, Taeniosis
CompletedTechnical University of Munich29212019-06-012023-11-30
Treatment of Patients With Active Neurocysticercosis in Eastern Africa
Neurocysticercosis
CompletedTechnical University of Munich632019-04-012023-11-30
Digital Health Promotion in Iringa, Tanzania
Digital health promotion intervention - HIV Infections, Tuberculosis
Not applicableCompletedUniversity of Oslo6002019-04-012020-11-04
The Burden of (Neuro)Cysticercosis Among People Living With HIV in Rural Tanzania
Diagnosis of (Neuro)cysticercosis - Neurocysticercosis, HIV/AIDS
CompletedTechnical University of Munich25842018-04-012023-11-29
Sub Arachnoid Neurocysticercosis Treatment Outcome (SANTO)
Albendazole and praziquantel, Albendazole and praziquantel placebo - Neurocysticercosis
Phase 3TerminatedUniversidad Peruana Cayetano Heredia1072016-11-142022-11-16
Two Cases of Pulmonary Cysticercosis Manifesting as Pleural Effusion: Case Report and Literature Review
Cysticercosis
CompletedSecond Affiliated Hospital, Zhejiang University, School of Medicine22016-10-222021-08-30
Single Ascending Dose Safety Study of Oxfendazole
oxfendazole, placebo - Tenia Solium Infection
Phase 1WithdrawnJohns Hopkins Bloomberg School of Public Health2016-08-012016-08-30
Treatment of Peri-calcification Edema in Neurocysticercosis (NCC)
Acetazolamide, Dexamethasone - Neurocysticercosis
Phase 2 / Phase 3TerminatedUniversidad Peruana Cayetano Heredia42015-12-042025-04-01
Phase I Trial Evaluating the Safety and Pharmacokinetics of Oxfendazole
Oxfendazole, Placebo - Neurocysticercosis
Phase 1CompletedNational Institute of Allergy and Infectious Diseases (NIAID)702014-11-172020-11-02
People Presenting With Neurocysticercosis in North America
Neurocysticercosis
TerminatedNational Institute of Allergy and Infectious Diseases (NIAID)112014-09-032018-04-05
Effects of 2 Different Duration of Albendazole Therapy in Patients With Neurocysticercosis in Brain ≤ 5 Lesions on CT
7 days of albendazole 15 mg/kg/day, 28 days of albendazole 15 mg/kg/day - Neurocysticercosis
Phase 3CompletedAll India Institute of Medical Sciences972014-03-012016-01-01
Taenia Solium Control Case Study in Zambia
CLTS - Cysticercosis, Helminthiasis
Not applicableCompletedUniversity of Zambia11972012-04-012015-02-11
Targeted Screening for Taenia Solium Tapeworms
Niclosamide, Community education campaign - Taenia Solium Taeniasis
Not applicableCompletedOregon Health and Science University18112011-05-012014-10-24
EFECAB: Improving Pig Management to Prevent Epilepsy in Burkina Faso
Educational package - Cysticercosis
Not applicableCompletedUniversity of Oklahoma582011-02-212018-04-03
Neurocysticercosis: Combined Treatment With Praziquantel (PZQ) and Albendazole (ABZ)
Praziquantel, Albendazole, ABZ Placebo - Neurocysticercosis, Epilepsy
Phase 2 / Phase 3CompletedUniversidad Peruana Cayetano Heredia1562010-01-012015-06-11
PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [F-18]FB
[F-18]FBR - Neurocysticercosis, Healthy
Phase 1CompletedNational Institute of Mental Health (NIMH)242007-09-042018-07-05

Showing 20 of 26. Sign in to see all of them.

Narrower conditions

Neurocysticercosis (20)  ·  Taeniasis (10)  ·  Epilepsy (6)  ·  Seizures (5)  ·  Cestode Infections (3)  ·  Hydrocephalus (2)  ·  Neuroinflammatory Diseases (2)  ·  Acquired Immunodeficiency Syndrome (1)  ·  Communicable Diseases (1)  ·  Cysts (1)  ·  HIV Infections (1)  ·  Helminthiasis (1)  ·  Immune System Diseases (1)  ·  Meningitis, Aseptic (1)

Broader conditions

Infections (26)  ·  Helminthiasis (25)  ·  Parasitic Diseases (25)  ·  Cestode Infections (23)  ·  Nervous System Diseases (22)  ·  Central Nervous System Diseases (21)  ·  Central Nervous System Helminthiasis (20)  ·  Central Nervous System Infections (20)  ·  Central Nervous System Parasitic Infections (20)  ·  Taeniasis (16)  ·  Brain Diseases (8)  ·  Pathological Conditions, Signs and Symptoms (8)  ·  Signs and Symptoms (5)  ·  Neurologic Manifestations (4)

Interventions

Albendazole (8)  ·  Dexamethasone (3)  ·  Praziquantel (3)  ·  oxfendazole (3)  ·  Acetazolamide (1)  ·  Niclosamide (1)  ·  Omeprazole (1)  ·  Phenytoin (1)

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID) (5)  ·  Universidad Peruana Cayetano Heredia (4)  ·  Technical University of Munich (3)  ·  All India Institute of Medical Sciences (2)  ·  National Institute of Mental Health (NIMH) (2)  ·  Cephas Health Research Initiative Inc, Ibadan, Nigeria (1)  ·  Columbia University (1)  ·  Johns Hopkins Bloomberg School of Public Health (1)  ·  Johns Hopkins University (1)  ·  Oregon Health and Science University (1)  ·  R-Evolution Worldwide S.r.l. Impresa Sociale (1)  ·  Second Affiliated Hospital, Zhejiang University, School of Medicine (1)  ·  University of Oklahoma (1)  ·  University of Oslo (1)  ·  University of Zambia (1)

Countries

Peru (6)  ·  United States (6)  ·  Tanzania (3)  ·  Zambia (2)  ·  Burkina Faso (1)  ·  Ecuador (1)  ·  India (1)

Top investigators

Hector H. Garcia, MD, PhD (2)  ·  Masahiro Fujita, M.D. (2)  ·  Ajay Garg, MD DM (1)  ·  Andrea S Winkler, M, PhdD (1)  ·  Armando Gonzalez, DVM PhD (1)  ·  Arunmozhimaran Elavarasi, MD DM (1)  ·  Bernard J Ngowi, MD, PhD (1)  ·  Chummy S. Sikasunge, PhD (1)  ·  Chummy Sikasunge, PhD (1)  ·  E. Javier Pretell, MD (1)  ·  Elise M O'Connell, M.D. (1)  ·  Evans K. Mwape, MSc (1)  ·  Giveson Zulu, PhD (1)  ·  Hector H Garcia, MD, PhD (1)  ·  Hector H. Garcia Lescano, Ph.D (1)

Results publications

PMID 18495737, PMID 21332573, PMID 24999157, PMID 26984901, PMID 28569208, PMID 29749279, PMID 30653519, PMID 30745383, PMID 33885369, PMID 35900820, PMID 36961623, PMID 37983246, PMID 8615453, PMID 9364715, PMID 9840607

NIH funding

R01NS054805 (1), R21NS069275 (1)